Oniria Therapeutics

Executive Summary

Oniria Therapeutics is a Barcelona-based preclinical biotechnology company founded in 2020, dedicated to developing innovative oncology therapies that target dormant cancer cells. By exploiting vulnerabilities in latent tumor cells, the company aims to prevent cancer recurrence and metastasis, addressing a critical unmet need in cancer treatment. Its approach is distinct from traditional therapies that often fail to eliminate persister cells, leading to disease relapse. Oniria's platform targets the unique biology of dormant cells, with potential applicability across multiple cancer types. As a preclinical-stage company, Oniria faces significant development risks, including the need for substantial capital to advance its lead program into clinical trials. The company has not disclosed specific funding rounds or partnerships, suggesting it may be operating with limited resources. However, if successful, its technology could represent a paradigm shift in oncology, offering a path to durable remissions. Near-term catalysts include candidate selection and entry into IND-enabling studies, which will be critical for demonstrating proof-of-concept and attracting further investment.

Upcoming Catalysts (preview)

• Q3 2026Lead development candidate selection50% success
• Q4 2026Series A or strategic partnership announcement30% success